Home › Companies › Lineage Cell Therapeutics, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Lineage Cell Therapeutics, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of June 10, 2026: 9 items on Lineage Cell Therapeutics, Inc.’s Form 8-K, filed June 12, 2026: 7 elected · 2 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore Lineage Cell Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Lineage Cell Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Michael H. Mulroy | 90,383,337 | -- | -- | 1,201,448 | 73,917,854 | 99% | Elected | — |
| Elect Director: Dipti Amin | 90,428,362 | -- | -- | 1,156,423 | 73,917,854 | 99% | Elected | — |
| Elect Director: Deborah Andrews | 90,328,622 | -- | -- | 1,256,163 | 73,917,854 | 99% | Elected | — |
| Elect Director: Angus C. Russell | 90,464,859 | -- | -- | 1,119,926 | 73,917,854 | 99% | Elected | — |
| Elect Director: Neal C. Bradsher | 90,514,702 | -- | -- | 1,070,083 | 73,917,854 | 99% | Elected | — |
| Elect Director: Brian M. Culley | 89,917,990 | -- | -- | 1,666,795 | 73,917,854 | 98% | Elected | — |
| Elect Director: Anula Jayasuriya | 90,549,317 | -- | -- | 1,035,468 | 73,917,854 | 99% | Elected | — |
| 2. The appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes | 163,825,928 | 659,670 | 1,017,041 | -- | -- | 99.5% | Approved | — |
| 3. The compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes | 88,328,168 | 2,600,932 | 655,685 | -- | 73,917,854 | 97% | Approved | — |
This meeting is also recorded here as June 9, 2026; both records come from the same filing, so the date should be checked against it.
Source: Lineage Cell Therapeutics, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.
Each item below shows how the 100 asset managers that disclosed a Lineage Cell Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Angus C. Russell
Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Angus C. Russell”): 90,464,859 for, 1,119,926 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,707,257 | 0 | 4 | 18,058 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Anula Jayasuriya
Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Anula Jayasuriya”): 90,549,317 for, 1,035,468 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,512,147 for, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,725,315 | 0 | 3 | 0 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Brian M. Culley
Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Brian M. Culley”): 89,917,990 for, 1,666,795 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 98% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,494,087 for, 18,058 withheld, 6 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,707,255 | 0 | 6 | 18,058 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Deborah Andrews
Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Deborah Andrews”): 90,328,622 for, 1,256,163 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,707,257 | 0 | 4 | 18,058 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Dipti Amin
Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Dipti Amin”): 90,428,362 for, 1,156,423 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,512,146 for, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,725,314 | 0 | 4 | 0 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Michael H. Mulroy
Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael H. Mulroy”): 90,383,337 for, 1,201,448 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,707,257 | 0 | 4 | 18,058 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect seven directors to hold office until the 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified: Neal C. Bradsher
Lineage Cell Therapeutics, Inc.’s own tally for this item (“Elect Director: Neal C. Bradsher”): 90,514,702 for, 1,070,083 withheld, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Shareholders elected the seven nominees named below to the Company's board to hold office until the Company's 2027 annual meeting of shareholders and until their respective successors are duly elected and qualified by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,494,089 for, 18,058 withheld, 4 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,707,257 | 0 | 4 | 18,058 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Combines 6 wordings of this item as funds reported it.
97% Approved · of votes cast
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS.
Lineage Cell Therapeutics, Inc.’s own tally for this item (“3. The compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes”): 88,328,168 for, 2,600,932 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Shareholders approved, on an advisory basis, the compensation paid to the Company's named executive officers, as set forth in the Proxy Statement, by the following votes:”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,725,306 | 10 | 3 | 0 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Fund voting reports, all 10 managers: 9,512,138 for, 10 against, 3 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RAFFLES ASSOCIATES LP | 4,101,438 | 0 | 0 | 0 | For |
| BlackRock | 1,214,193 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 1,129,570 | 0 | 0 | 0 | For |
| Northern Trust | 490,988 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 390,166 | 0 | 0 | 0 | For |
| State Street | 324,211 | 0 | 0 | 0 | For |
| Informed Momentum Co LLC | 217,646 | 0 | 0 | 0 | For |
| Fidelity | 190,931 | 0 | 0 | 0 | For |
| Vanguard | 180,279 | 0 | 0 | 0 | For |
| STIFEL NICOLAUS & CO INC \MO\ | 147,113 | 0 | 0 | 0 | For |
| Donor Advised Charitable Giving, Inc. | 0 | 0 | 0 | 0 | Not Voted |
| Renaissance | 118,726 | 0 | 0 | 0 | For |
| CIBC Capital Markets (Europe) S.A. | 47,050 | 0 | 0 | 0 | For |
| CIBC WORLD MARKET INC. | 47,050 | 0 | 0 | 0 | For |
| TRUST CO OF TOLEDO NA /OH/ | 33,795 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 29,720 | 0 | 0 | 0 | For |
| Voleon Capital Management LP | 25,363 | 0 | 0 | 0 | For |
| Goldman Sachs | 24,653 | 0 | 0 | 0 | For |
| Two Sigma | 22,206 | 0 | 0 | 0 | For |
| Fifth Third Wealth Advisors LLC | 20,000 | 0 | 0 | 0 | For |
| GC Wealth Management RIA, LLC | 18,713 | 0 | 0 | 0 | For |
| Founders Capital Management | 16,000 | 0 | 0 | 0 | For |
| WELLS FARGO CLEARING SERVICES, LLC | 15,011 | 0 | 0 | 0 | For |
| Fisher Asset Management, LLC | 13,096 | 0 | 0 | 0 | For |
| Piscataqua Savings Bank | 12,499 | 0 | 0 | 0 | For |
Institutional-manager reports, all 95 managers: 8,998,973 for, 177 against, 130,200 not voted. Showing the 25 largest; see all in the interactive database.
99.5% Approved · of votes cast
Description as filed by funds: To ratify the appointment of Baker Tilly US, LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2026.
Lineage Cell Therapeutics, Inc.’s own tally for this item (“2. The appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes”): 163,825,928 for, 659,670 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Shareholders ratified the appointment of Baker Tilly US, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 by the following votes:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 10 asset managers below reported 9,512,148 for, 1 against, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,725,316 | 1 | 1 | 0 | For |
| BlackRock | 1,143,785 | 0 | 0 | 0 | For |
| Fidelity | 607,818 | 0 | 0 | 0 | For |
| Goldman Sachs | 9,748 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 9,600 | 0 | 0 | 0 | For |
| Charles Schwab | 6,569 | 0 | 0 | 0 | For |
| Lincoln Financial | 4,300 | 0 | 0 | 0 | For |
| John Hancock | 3,995 | 0 | 0 | 0 | For |
| Guggenheim | 747 | 0 | 0 | 0 | For |
| Victory Capital | 270 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 249,298,295 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.10% |
| 2 | BlackRock | 0.46% |
| 3 | Fidelity | 0.24% |
| 4 | Goldman Sachs | <0.01% |
| 5 | BRIDGEWAY FUNDS INC | <0.01% |
| 6 | Charles Schwab | <0.01% |
| 7 | Lincoln Financial | <0.01% |
| 8 | John Hancock | <0.01% |
| 9 | Guggenheim | <0.01% |
| 10 | Victory Capital | <0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RAFFLES ASSOCIATES LP | 1.65% |
| 2 | BlackRock | 0.49% |
| 3 | GEODE CAPITAL MANAGEMENT, LLC | 0.45% |
| 4 | Northern Trust | 0.20% |
| 5 | MARSHALL WACE, LLP | 0.16% |
| 6 | State Street | 0.13% |
| 7 | Informed Momentum Co LLC | 0.09% |
| 8 | Fidelity | 0.08% |
| 9 | Vanguard | 0.07% |
| 10 | STIFEL NICOLAUS & CO INC \MO\ | 0.06% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Broadwood Partners, L.P. | 20.07% | DEF14A |
| Neal C. Bradsher | 20.07% | DEF14A |
| Vanguard Group | 3.87% | 13F |
| Brian M. Culley | 3.53% | DEF14A |
| Millennium Management | 2.23% | 13F |
| BlackRock | 1.55% | 13F |
| Geode Capital | 1.01% | 13F |
| George A. Samuel III | 1.00% | DEF14A |
| Renaissance Technologies | 0.85% | 13F |
| Morgan Stanley | 0.80% | 13F |
Percentages above are of 249,298,295 shares outstanding, as reported by Lineage Cell Therapeutics, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Lineage Cell Therapeutics, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At Lineage Cell Therapeutics, Inc.'s shareholder meeting held June 10, 2026, in the 2025-2026 proxy season, 100 asset managers reported how they voted on 9 ballot items in their SEC Form N-PX filings, covering 333 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS. — Lineage Cell Therapeutics, Inc.'s filing reports the proposal as approved, with 97% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Lineage Cell Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.
Lineage Cell Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Download data (CSV): ballot items · votes by manager · column guide.